73 results about "Mitotic nucleus" patented technology

A method and system for morphology based mitosis identification and classification of digital images. Luminance parameters such as intensity, etc. from a digital image of a biological sample (e.g., tissue cells) to which a chemical compound (e.g., a marker dye) has been applied are analyzed and corrected if necessary. Morphological parameters (e.g., size, elongation ratio, parallelism, boundary roughness, convex hull shape, etc.) from individual components within the biological sample are analyzed. A medical conclusion (e.g., type and count of mitotic cells) or a life science and biotechnology experiment conclusion is determined from the analyzed luminance and morphological parameters. The method and system may be used to develop applications for automatically obtaining a medical diagnosis (e.g., a carcinoma diagnosis).

The present invention provides for compounds, compositions, methods and systems for inhibiting cell growth. More specifically, the present invention provides for methods, compounds and compositions which are capable of inhibiting mitosis in metabolically active cells. Compounds, compositions and methods of the present invention inhibit the activity of a protein involved in the assembly and maintenance of the mitotic spindle. One class of proteins which acts on the mitotic spindle is the family of mitotic kinesins, a subset of the kinesin superfamily.

A method for the automated analysis of digital images, particularly for the purpose of assessing mitotic activity from images of histological slides for prognostication of breast cancer. The method includes the steps of identifying the locations of objects within the image which have intensity and size characteristics consistent with mitotic epithelial cell nuclei, taking the darkest 10% of those objects, deriving contours indicating their boundary shape, and smoothing and measuring the curvature around the boundaries using a Probability Density Association Filter (PDAF). The PDAF output is used to compute a measure of any concavity of the boundary—a good indicator of mitosis. Objects are finally classified as representing mitotic nuclei or not, as a function of boundary concavity and mean intensity, by use of a Fisher classifier trained on known examples. Other uses for the method could include the analysis of images of soil samples containing certain types of seeds or other particles.

The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.

Disclosed herein are methods of inhibiting proliferation of a cancer cell or inducing apoptosis of a cancer cell, which does not overexpress N—CoR. Also disclosed herein are methods of inhibiting proliferation or inducing apoptosis of a cancer cell that overexpresses TCTP and methods for determining whether a compound is effective in inducing cell death.

The present invention discloses a rice large-grain gene GW2 and the application thereof, the GW2 gene can be used to control the grain size of the crop, improve the yield or quality of the crop, regulate the cycle duration of cellular mitosis, and used as a molecular marker to identify the species of the crop to be a large-grain one or a small-grain one. The present invention also discloses a method to ameliorate the crop. The gene GW2 has a wide prospect on high-yield breeding of crops such as rice.

Disclosed are compounds and pharmaceutically acceptable salts of Formula I: wherein n, R1, R2, R3, X, R4, R5, R6, R8, R9, and Y are as defined herein. Compounds of Formula I are useful in the treatment of diseases and / or conditions related to cell proliferation and / or abnormal cell mitosis, such as cancer, inflammation and inflammation-associated disorders, and conditions associated with angiogenesis. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

The invention relates to the field of medicinal chemistry, and discloses three crystal forms of cabazitaxel, i.e., an ester compound crystal form J of cabazitaxel, a hydrate crystal form G of cabazitaxel and a cabazitaxel crystal form I, and a preparation method of a novel crystal form of cabazitaxel. The novel cabazitaxel form has superior performance on the aspects of oral absorptivity, activation of metabolism and suppression of mitosis and interval cell function of cells, is weak in toxicity, has high storing and treating stability, and can be applied to preparation of a medicament for treating prostatitis.

The application discloses novel synthetic compounds, modeled after unique toxins extracted from the marine invertebrate Diazona angulata useful in the treatment abnormal cell mitosis. The application also discloses novel methods for synthesis of these compounds and methods of using these compounds.

Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptor system can be manipulated positively or negatively to regulate mitosis in neuronal precursor cells. The ligand / receptor system involves PACAP, PACAP receptor, PAC1, and related antagonists. The methods of regulation of the present invention may model be used to define cell cycle regulation in the developing neurons. The present invention may also be used to control or cure diseases related to or caused by damage to or destruction of neuronal cells.

To prevent intimal hyperplasia within a dialysis graft, a flexible tube comprising the dialysis graft is coated interiorly before placement with an anticarcinogen or mitosis-inhibiting agent for preventing cell division. The graft can also be irradiated with light energy by directing light into the lumen of the tube that has been grafted in place, thereby preventing or reducing dialysis graft intimal hyperplasia and reducing inflammation. The light source can be a light emitting diode (LED) or a chemical light source, i.e., a chemiluminescent substance for producing cool light energy within the graft to prevent or reduce the symptoms of GIH. When phototherapy is used, the body is exposed to light radiation at the site of the graft in sufficient amount to prevent undesired cell proliferation within the vessels, the graft, or surrounding tissue where the invention is used without detectable damage to body tissue.

Diseases and disorders of dermal tissue such as the skin, hair and nails are treated or prevented by administering one or more lectins, capable of binding to the surface of pathogenic microorganisms inhabiting the hair, skin, and nails, or of binding to the superficial tissues that comprise hair, skin, and nails. The lectins may be administered topically or subcutaneously to a patient infected with pathogenic microorganisms or in danger of being exposed to such pathogens. Lectins that stimulate cell mitosis may also be administered to accelerate wound healing and restore the appearance of age-wrinkled skin. Lectins that coagulate blood can be administered to assist in stopping bleeding from skin lesions. The lectins may be applied to the skin in a pharmceutically acceptable vehicle.

Methods and compositions for determining the duration of a cell cycle phase of a mammalian cell, as well as identification of the cell cycle stage of fixed mammalian cells, are provided. In practicing the subject methods, at least one biosensor polypeptide that monitors a cell-cycle phase in a mammalian cell, such as mitosis, G1, S, or G2 phase, is used to determine the duration of a cell-cycle phase of a mammalian cell. Also provided are methods for identifying an agent (e.g., a gene product or small molecule compound) that modulates the duration of a cell-cycle phase of a mammalian cell, as well as kits and systems for practicing the subject methods.

The application discloses novel synthetic compounds, modeled after unique toxins extracted from the marine invertebrate Diazona angulata useful in the treatment abnormal cell mitosis. The application also discloses novel methods for synthesis of these compounds and methods of using these compounds.

The present invention is directed to the use of mitotically and / or lethally inactivated stem cells for the repair of damaged organs and / or tissues. Stem cells are mitotically and / or lethally inactivated and transplanted into damaged tissue. Any form of ex vivo inactivation of stem cells may be used such that the stem cells cannot undergo mitosis or cell division before in vivo application. Mitotically and / or lethally inactivated stem may be used to ameliorate numerous disease, injury, traumatic, ischemic, aging, and / or degenerative conditions in different types of organs and / or tissues.

FtsZ, the bacterial analog of tubulin, is a promising new target for developing new antibiotics. It has been shown that polyphenols inhibit the GTPase activity of FtsZ, thereby inhibiting Z-ring formation during mitosis. The present invention provides novel polyphenols compounds, which can be accessed by the synthesis of dichamametin and 2′″-hydroxy-5″-benzylisouvarinol-B as described herein. These novel compounds are useful in treating infections, particularly infections caused by gram-positive organisms. Methods of preparing the inventive compounds are also provided. The compounds are prepared by the benzylation of pinocembrin or chrysin core structure. Pharmaceutical compositions and method of using the compounds to treat disease are also provided. These compounds may be screened for antimicrobial activity as well as other biological activities such as anti-neoplastic, anti-inflammatory, immunosuppressive, and cytotoxic activity.

The invention provides a lymphocyte serum-free medium which comprises the following materials per liter: a basic culture medium, 10 mg of transferrin, 0.01 mg of sodium selenite, 110 mg of pyroracemic acid, 1.5 mg of ethanolamine, 10 mg of insulin, 10 to 30 mg of glutamine substitute, 300 mg of lipid-type bovine serum albumin, 0.001 mg of cupper sulfate, 0.0005 mg of ammonium meta-vanadate, 0.00005 mg of manganese chloride, 0.8 mg of zinc sulfate, 2 mg of Vitamin E, 100 mg of PHA, and 10 to 25 mg of an MHEPES / NaHCO3 buffering system. The invention further provides a preparation method and application to lymphocyte culture of the lymphocyte serum-free medium. The lymphocyte serum-free medium has the advantages that the repeatability of lymphocyte culture is high; poisoning and polluting of blood serum to lymphocyte are avoided; convenience is brought for differentiation of the lymphocyte, so as to obtain various mitosis phases.

The invention discloses a slow characteristic based cell division recognition method and a recognition device thereof. The method comprises the steps of extracting cell data by adopting a mode of unsupervised slow characteristic analysis so as to acquire a slow characteristic function; solving an accumulative square offset characteristic of the cell slow characteristic, and acquiring arrangement of variation rates of the slow characteristic from small to large; carrying out detection on the final accumulative square offset characteristic by using a method of model learning, and acquiring the probability of containing mitosis in the variation process of the cell data along with the time, wherein the test data contains mitosis if an output category label is 1, and the test data does not contain mitosis if the output category label is 0. The device comprises a first acquisition module, a second acquisition module, a third acquisition module and an output module. According to the invention, the difficulty of cell characteristic extraction is reduced, and the accuracy of cell characteristic extraction is improved, thereby providing good conditions for subsequent recognition and classification for dividing cells, and being convenient for recognition tracking and processing of the cells.

The present invention provides methods for treating cancer and other pathological proliferating conditions by inhibiting mitosis using at least one pyrrolo[2,3-d]pyrimidine having the general formula (16): where X is selected from the group consisting of lower alkyls, heteroalkyls, substituted or unsubstituted aryls or heteroaryls, arylalkyls, and heteroarylalkyls; where R1 is selected from the group consisting of hydrogen, lower alkyls, heteroalkyls, substituted or unsubstituted aryls or heteroaryls, arylalkyls, and heteroarylalkyls; where R2 is selected from the group consisting of hydrogen, lower alkyls, heteroalkyls, alkoxys, substituted or unsubstituted aryls or heteroaryls; where R3 is selected from the group consisting of zero, lower alkyls, heteroalkyls, alkenyls, and heteroalkenyls; and where R4 is selected from the group consisting of substituted or unsubstituted aryls or heteroaryls, arylalkyls, heteroarylalkyls, and hydrogen. The compound may inhibit mitosis in cells that have developed multidrug resistance due to P-glycoprotein and MRP1, and facilitate the reversal of P-glycoprotein mediated resistance.

The invention discloses a sexual polyploidization breeding method for tetraploid petunias. The method comprises the following steps: firstly, determining the sizes and the morphological characteristics of flower buds at a reduction mitosis prophase I of diploid petunias to grasp the optimal treatment period; carrying out inducing treatment with colchicines with optimal concentration for proper times, observing the sizes and the morphological characteristics of petunia 2n pollen and n pollen of the petunias to rapidly distinguish and identify the 2n pollen; carrying out sexual polyploidization hybridizing; and identifying ploidies of hybridized F1 plant of the petunias by a simple and easy cytology identification method. With the adoption of the breeding method, the obtained sexual polyploidization hybridized F1 not only has the characteristics of large volume of a parent polyploidy organ, but also has the inheritable characters from a diploid male parent; compared with an autotetraploid obtained by an asexual polyploidization manner, the tetraploid petunias have wider genetic diversity, and higher ornamental value and seed setting rate.

Diseases and disorders of dermal tissue such as the skin, hair and nails are treated or prevented by administering one or more lectins, capable of binding to the surface of pathogenic microorganisms inhabiting the hair, skin, and nails, or of binding to the superficial tissues that comprise hair, skin, and nails. The lectins may be administered topically or subcutaneously to a patient infected with pathogenic microorganisms or in danger of being exposed to such pathogens. Lectins that stimulate cell mitosis may also be administered to accelerate wound healing and restore the appearance of age-wrinkled skin. Lectins that coagulate blood can be administered to assist in stopping bleeding from skin lesions. The lectins may be applied to the skin in a pharmceutically acceptable vehicle.

The invention belongs to the field of biomedicine and particularly relates to soluble human keratin and application thereof. The soluble keratin is obtained through the following process of cloning amiddle sequence of a human gene K37, constructing a recombinant vector, transforming bacteria, inducing expression of the recombinant protein and purifying the recombinant protein to obtain the soluble keratin. The soluble keratin has the characteristic of rapid swelling and can promote mitosis and migration of epidermal cells, and therefore the soluble keratin can be used for preparing biologicalmaterials or medicaments for promoting cell proliferation or migration, and plays a role in hemostasis and wound healing. Moreover, the soluble keratin causes no rejection phenomenon when being usedfor the human body, is safe to use and thus has a wide application prospect in the field of biomedicine.

The invention describes human genes involved in cell cycle progression, including mitosis and meiosis. The invention also relates to the use of these “cell cycle progression” genes and proteins in the modulation of cell cycle progression in cells and methods for identifying modulators of these genes or proteins and hence modulators of mitosis and meiosis.

The invention belongs to the field of functional foods and relates to a multi-component compounded functional solid drink for enhancing human immunity and a preparation method thereof. The functionalsolid drink comprises 20-30 parts of sorbitol, 15-25 parts of dried skim milk, 10-25 parts of resistant dextrin, 5-20 parts of xylooligosaccharide, 5-15 parts of yeast beta-glucan, 1-10 parts of bovine colostrum powder, 1-10 parts of orange powder, 1-10 parts of soybean peptide, 1-10 parts of fish collagen powder, 0.1-1 part of casein phosphopeptides, 0.1-1 part of composite amino acid powder and0.01-1 part of vitamin C. The functional solid drink is capable of improving human immunity from six aspects of stimulating immune cell regeneration, promoting mitosis of phagocyte, providing immunityactive factors, providing basic constitution substances for establishing cells of bodies, replenishing vitamin C and regulating intestinal tract health, and is high in security and remarkable in effect. The functional solid drink is prepared by using a modern process, multiple components are compounded, the components play a role of synergism, and the human immunity can be well improved; and compared with a conventional product in the market, the functional solid drink has a comprehensive replenishing function and good advantages.

The invention relates to a caper extract, a caper cream and a production method thereof. The caper extract contains 1.2-2.0 percent total alkaloids according to the weight percentage. Raw materials of the caper cream comprise caper, stearic acid, glycerin monostearate, white Vaseline, glycerin, sodium dodecyl sulfate, laurocapram and ethyl p-hydroxybenzaote. The pharmacodynamic test results show that the caper cream can significantly promote the formation of epidermal granular layer in the scales of mouse-tail., significantly inhibit the mitosis of mouse vaginal epithelial cells, reduce the dextran-induced mouse itching times and the itching sustained total time, inhibit the xylene-induced mouse auricula edema and the acetic acid-induced mouse peritoneal capillary permeability increase and promote the generation of mouse hemolysin antibody. The preparation is prompted to have better therapeutic effect for mouse scleroderma and psoriasis. The caper cream has good transdermal absorption, durable action, no irritation and easy smearing, washing and removal by patients.

The invention provides a gossypium raimondii functional centromere sequence and a molecular marker of the same. IN the invention, a method of combination of chromatin co-immunoprecipitation and high throughput sequencing (ChiP-Seq) is employed to obtain four DNA sequences in a functional centromere zone of gossypium raimondii, and primers are respectively designed according to the sequences for fluorescence in-situ hybridization (FISH) of mitosis metaphase of the gossypium raimondii. A result proves that all the four sequences generate concentrated, clear and bright signals in the centromere zone of all chromosomes. The centromere sequence can be directly used for positioning the functional centromeres and identification of relative sequences. The molecular marker can be used in genetic location of the centromere of a genetic map of cotton, can provide more accurate information to functional gene location and linkage relationship and can provide basis for sequence splicing of whole genome sequencing of the gossypium raimondii, so that the information of a physical map can be more comprehensive.

A cell-free assay system, which reconstitutes components of the phosphatidyl-inositol 3-kinase-mediated insulin signaling pathway including phosphatidylinositol phosphate dependent kinase-2 (“PDK2”). Alternatively, a in vitro method for phosphorylating a protein kinase B on Serine 473 or Serine 474. The invention relates generally to an in vitro method of phosphorylating a protein kinase B (“PKB” or “Akt”), to an in vitro method of assessing insulin action, and to an in vitro method of identifying an agent or process that modulates insulin signaling or any cellular activity regulated or influenced by PKB, including cell growth, mitosis, apoptosis, fuel metabolism, and oncogenic transformation. Such an agent or process may be useful in treating insulin resistance, diabetes, obesity, cancer, and a number of other diseases.